S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NASDAQ:STSA

Satsuma Pharmaceuticals (STSA) Stock Forecast, Price & News

$1.05
-0.02 (-1.87%)
(As of 06/2/2023 ET)
Compare
Today's Range
$1.02
$1.08
50-Day Range
$0.66
$1.08
52-Week Range
$0.59
$8.08
Volume
247,575 shs
Average Volume
698,751 shs
Market Capitalization
$34.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.40

Satsuma Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
604.8% Upside
$7.40 Price Target
Short Interest
Healthy
0.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.25
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.82) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

116th out of 983 stocks

Pharmaceutical Preparations Industry

45th out of 486 stocks


STSA stock logo

About Satsuma Pharmaceuticals (NASDAQ:STSA) Stock

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Receive STSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

STSA Stock News Headlines

Why did Biden repeal Trump's Executive Order?!
" Why did Biden repeal Trump's Executive Order?! Within 10 days of taking office, President Trump signed "Executive Order 13771" in an effort to win the battle for what 60 minutes said could be "the most consequential discovery in biomedicine this century." So why did Biden repeal this? Click here to learn more >>> "
STSA Satsuma Pharmaceuticals, Inc.
Why did Biden repeal Trump's Executive Order?!
" Why did Biden repeal Trump's Executive Order?! Within 10 days of taking office, President Trump signed "Executive Order 13771" in an effort to win the battle for what 60 minutes said could be "the most consequential discovery in biomedicine this century." So why did Biden repeal this? Click here to learn more >>> "
Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical
SNBL to Acquire Satsuma Pharmaceuticals
8-K: Satsuma Pharmaceuticals, Inc.
See More Headlines

STSA Price History

STSA Company Calendar

Last Earnings
3/28/2023
Today
6/02/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Regional Banks
Sector
Medical
Current Symbol
NASDAQ:STSA
CUSIP
85931930
Fax
N/A
Employees
21
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$7.40
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+598.1%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-70,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.14 per share

Miscellaneous

Free Float
22,809,000
Market Cap
$35.14 million
Optionable
Not Optionable
Beta
0.10

Social Links


Key Executives

  • Mr. John A. Kollins MBA (Age 59)
    Pres, CEO & Director
    Comp: $830k
  • Mr. Thomas P. O'Neil (Age 57)
    Chief Financial Officer
    Comp: $550.08k
  • Dr. Detlef F. Albrecht (Age 61)
    Chief Medical Officer
    Comp: $625.97k
  • Mr. Mic Iwashima (Age 44)
    VP & Head of Operations
  • Mr. Robert Schultz (Age 58)
    Sr. VP & Head of Chemistry, Manufacturing and Controls
  • Dr. Shannon Strom Ph.D. (Age 46)
    VP & Head of Regulatory Affairs
  • Mr. Robert M. Janosky
    Chief Commercial Officer













STSA Stock - Frequently Asked Questions

Should I buy or sell Satsuma Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" STSA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STSA, but not buy additional shares or sell existing shares.
View STSA analyst ratings
or view top-rated stocks.

What is Satsuma Pharmaceuticals' stock price forecast for 2023?

5 Wall Street research analysts have issued 1 year price objectives for Satsuma Pharmaceuticals' shares. Their STSA share price forecasts range from $2.00 to $15.00. On average, they anticipate the company's share price to reach $7.40 in the next year. This suggests a possible upside of 598.1% from the stock's current price.
View analysts price targets for STSA
or view top-rated stocks among Wall Street analysts.

How have STSA shares performed in 2023?

Satsuma Pharmaceuticals' stock was trading at $0.90 on January 1st, 2023. Since then, STSA shares have increased by 17.8% and is now trading at $1.06.
View the best growth stocks for 2023 here
.

Are investors shorting Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 130,100 shares, a drop of 58.0% from the April 30th total of 310,100 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.5% of the company's shares are short sold.
View Satsuma Pharmaceuticals' Short Interest
.

When is Satsuma Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our STSA earnings forecast
.

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) posted its earnings results on Tuesday, March, 28th. The financial services provider reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.32.

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA).

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an IPO on Friday, September 13th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

What is Satsuma Pharmaceuticals' stock symbol?

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

Who are Satsuma Pharmaceuticals' major shareholders?

Satsuma Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Two Sigma Advisers LP (0.83%), Renaissance Technologies LLC (0.50%), FNY Investment Advisers LLC (0.14%) and Bank of America Corp DE (0.11%). Insiders that own company stock include Braden Michael Leonard, Commodore Capital Lp and Thomas P O'neil.
View institutional ownership trends
.

How do I buy shares of Satsuma Pharmaceuticals?

Shares of STSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Satsuma Pharmaceuticals' stock price today?

One share of STSA stock can currently be purchased for approximately $1.06.

How much money does Satsuma Pharmaceuticals make?

Satsuma Pharmaceuticals (NASDAQ:STSA) has a market capitalization of $35.14 million. The financial services provider earns $-70,060,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How can I contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The official website for the company is www.satsumarx.com. The financial services provider can be reached via phone at 650-410-3200 or via email at cdavis@lifesciadvisors.com.

This page (NASDAQ:STSA) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -